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Summary 
The fifth Åland Island meeting on von Willebrand disease (VWD) was held on the Åland Islands, 
Finland, from 22 to 24 September 2016 ± 90 years after the first case of VWD was diagnosed in a patient 
from the Åland Islands in 1926. This meeting brought together experts in the field of VWD to share 
knowledge and expertise on current trends and challenges in VWD. Topics included the storage and 
release of von Willebrand factor (VWF), epidemiology and diagnostics in VWD, treatment of VWD, 
angiogenesis, and VWF inhibitors. 
Keywords: Angiodysplasia, angiogenesis, factor VIII, genetics, pregnancy, von Willebrand disease, 
von Willebrand factor, surgery 
Introduction 
In 1926, (ULNYRQ:LOOHEUDQGSXEOLVKHGDQDUWLFOHRQDGLVRUGHUµ+HUHGLWlUSVHXGRKHPRILOL¶, which later 
became known as von Willebrand disease (VWD) [1]. Over the next 90 years, there have been many 
advances in our understanding of the underlying mechanisms, pathogenesis and treatment of VWD. 
VWD has been reported to affect up to approximately 1% of the general population and is the most 
common bleeding disorder. VWD is clinically heterogeneous and is classified into three main categories 
based on distinct quantitative and qualitative abnormalities in von Willebrand factor (VWF) [2-4]. Type 
1 VWD is the most common form (~70±75% of all cases) and is characterized by a partial quantitative 
deficiency in functional normal VWF. Type 3 VWD (~1±3% of cases) is characterized by a severe 
quantitative deficiency in VWF together with very low plasma factor VIII coagulant activity (FVIII:C). 
Type 2 VWD (~20% of cases) is characterized by qualitative deficiencies in VWD and is further 
subdivided into 2A, 2B, 2M and 2N subtypes. 
The fifth Åland Islands 2016 meeting, which coincided with the 90th anniversary of the first VWD case 
description by Erik von Willebrand in a 5-year-old girl named Hjördis S from the Åland islands, brought 
together experts in VWD to discuss the latest scientific and clinical knowledge on VWD. 
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VWF structure and function 
Nanoscopic view on VWF structure and Weibel-Palade bodies 
Weibel-Palade bodies (WPBs) are storage organelles for VWF in endothelial cells (Fig. 1A) [5, 6]. After 
its synthesis in the endoplasmic reticulum, VWF pre-pro-proteins undergo cleavage and go on to form 
multimers [6]. WPBs are first formed in the trans-Golgi network and, as WPBs develop, the stored VWF 
is assembled into tubules [6, 7]. During maturation of the WPBs, VWF tubules grow and WPBs become 
elongated and more protein-dense [6, 8, 9]. At the end of this process, other co-stored proteins are also 
packaged into the WPB granules [6]. Upon stress stimulation, such as injury or inflammation, mature 
WPBs are transported to the plasma membrane [6]. VWF is then secreted into blood vessels via 
exocytosis where it structurally rearranges into strings to capture platelets and initiate primary 
haemostasis [6].  
In order to elucidate the mechanistic details of the WPB life cycle, biogenesis of WPBs was followed 
using various ultrastructure imaging techniques [10-12] (Fig. 1B±D). WPBs were first depleted from 
human umbilical cord venous endothelial cells (HUVECs) by phorbol 12-myristate 13-acetate (PMA) 
treatment, which induces exocytosis of WPBs [11]. Synthesis of nascent WPBs over time was then 
followed by visualization of VWF. Confocal microscopy and transmission electron microscopy analyses 
of immunofluorescence- and immunogold-labelled VWF, respectively, showed the appearance of newly 
formed WPB-like structures containing VWF tubules after 4 hours of recovery from PMA treatment 
[11]. These findings were then confirmed using correlative light and electron microscopy (CLEM), 
which combines confocal microscopy with conventional transmission electron microscopy, using 
transfected HUVECs expressing enhanced green fluorescent protein (EGFP)-tagged VWF propeptide 
[10, 11] (Fig. 1B). The CLEM analysis revealed that 4 hours after transfection, early electron-lucent 
WPBs began to appear and that 6 and 8 hours after transfection they appeared denser and more elongated. 
The 3D morphology of nascent WPBs was also investigated by electron tomography as well as serial 
block face scanning electron microscopy (Fig. 1C±D), where a focussed ion beam removes layers of 
sample material in between cycles of scanning electron microscopy imaging [11, 12]. This showed that 
WPBs are tightly associated with the Golgi through numerous connections during their formation. As 
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WPBs develop, non-tubular VWFs are delivered from the Golgi to the lumen of the WPBs through these 
connections and once inside VWFs rearrange into tubules. Interestingly, the WPB-Golgi connections 
continue to be maintained 8 hours after transfection of the labelled propeptide when dense elongated 
WPBs are already visible [11]. Findings from this nanostructure imaging study, where WPBs remain 
closely Golgi-associated until maturation, are in line with results from a separate study using super 
resolution microscopy [13].  
There are several modes of VWF secretion from mature, stimulated WPBs [14, 15]. Single WPBs can 
exocytose individually and several WPBs may fuse intracellularly to produce large secretory pods prior 
to release of VWF [16]. Live-cell imaging in HUVECs confirmed that large secretory pods are formed 
through coalescence of multiple WPBs shortly before secretion [17]. The analysis also revealed that 
VWF adopts a globular conformation immediately after exocytosis and remains anchored to the cell 
periphery for structural remodelling to form strings [17]. Under more physiological conditions using a 
flow chamber, the extension of VWF strings was predominantly observed at the edge of cells, which 
suggests this structural remodelling process may be facilitated by surface receptors such as integrins 
[17]. $QRWKHUPRGHRIVHFUHWLRQLVNQRZQDVWKH³OLQJHULQJNLVV´ZKHUHVPDOOHUFR-stored cargo in WPBs, 
such as interleukins, are selectively released while VWF is retained intracellularly [14]. 
Genetic mutations in a discrete region of the VWF gene have been associated with VWD patients who 
are non-responders or partial responders to desamino D-arginine vasopressin (DDAVP), which acts to 
induce VWF secretion from endothelial cells [18]. However, the mechanism underlying the response to 
DDAVP is likely to be very complex as similar mutations are found in both non-responders and 
responders [18]. In a cell-based study, these VWF mutations were studied in more detail by their 
transient expression in HEK293 cells [19]. Key mutant phenotypes included the inability to form mature 
elongated WPBs, retention of VWF in the endoplasmic reticulum and reduced VWF secretion upon 
PMA stimulation. These findings suggest that impairment at different stages of the WPB life cycle, 
including release of VWF and string formation, may play a role in the pathogenesis of VWD [19, 20]. 
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Advances in cell imaging techniques have greatly improved our knowledge of the physiological and 
pathophysiological processes involved in the storage and release of VWF. Impaired VWF storage, 
release and string formation seem to be potential pathophysiological mechanisms in VWD. 
VWD epidemiology and diagnostics 
Diagnosing type 1 VWD  
Although laboratory tests can generally distinguish type 1 VWD from other subtypes, the diagnosis of 
type 1 VWD remains challenging. Diagnosis of type 1 VWD is complicated by the high frequency of 
bleeding symptoms in the general population, the overlap of VWF level ranges in non-VWD individuals 
and VWD patients, and the lack of a strict relationship between VWF level and the severity and 
frequency of bleeding [21-23]. The continuous spectrum from severe VWD to non-affected individuals 
presents difficulties for setting decisional thresholds to distinguish those affected from those not affected. 
This is evident in the variation in reported prevalence estimates, which span 2 to 3 orders of magnitude. 
The prevalence is estimated to be 1 in 100 based on population-based studies and 1 in 1000 or 1 in 
10,000 in specialized centres and most review articles [24-28]. 
The aim of diagnosis should be to achieve a positive clinical outcome after a diagnosis. The outcome of 
diagnosis can be viewed in terms of diagnostic utility (patient perspective) and diagnostic accuracy 
(physician perspective) [21]. As clinicians, we should pursue a clinically useful diagnosis, which means 
that the diagnosis should be of some benefit for the patient and not simply be accurate (i.e. a diagnosis 
not biased by high false positive or negative rates) [21]. However, this is a particularly difficult task in 
mild bleeding disorders such as type 1 VWD. 
Collaborative studies on large cohorts of patients with mainly type 1 VWD have demonstrated the utility 
of a bleeding assessment tool (BAT) in diagnosis [29-32]. In the first of these studies, an international 
multicentre study (Vicenza BAT study) [29], the number of bleeding symptoms, especially the 
quantitative bleeding score, identified patients with type 1 VWD with a high discriminative power. 
Males and females with bleeding scores of >3 or >5, respectively, were 70 times more likely to have 
VWD compared with non-affected individuals [29]. Furthermore, bleeding score has been shown to 
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predict bleeding risk in patients with VWD [33] and to correlate with VWD severity [34]. Subsequent 
studies using modified versions of the Vicenza BAT have confirmed the usefulness of BATs as a 
screening tool for the diagnosis of type 1 VWD [30-32, 35]. In 2010, the International Society on 
Thrombosis and Haemostasis (ISTH) proposed a single BAT to standardize reporting of bleeding 
symptoms for use in adult and paediatric populations [36]. In addition, a self-administered BAT based 
on the ISTH-BAT has been developed [37]. 
Using the distribution of VWF in non-affected and affected individuals, the likelihood ratio of having 
VWD based on each class of VWD values can be calculated. This likelihood ratio was also useful in the 
diagnosis of type 1 VWD in the MCMDM-1VWD study [30]. There was a steep increment of the 
likelihood ratio of VWD when VWF antigen content (VWF:Ag) and VWF ristocetin cofactor activity 
(VWF:RCo) values were below 40 IU dL-1 and a 5-fold decrease of the likelihood ratio of VWD for 
values above 60 IU dL-1 [30]. Using a Bayes theorem approach, a combination of likelihood ratios from 
bleeding scores, VWF:Ag level, and number of family members with plasma VWF lower than the 2.5 
percentile were shown to influence the final odds of VWD [38]. Based on these observations, minimum 
criteria of significantly elevated bleeding score (>3 or >5 in men and women, respectively) and VWF:Ag 
or VWF:RCo levels <40 IU dL-1 (either confirmed or consistently reported in patient clinical records) 
have been proposed [25] (Fig. 2). 
With these minimal criteria, the Bayesian calculation allows the estimation of the probability of having 
VWD as 80/100 (80%) [25]. Using this approach, 1 in 5 of patients would be incorrectly classified, 
which can be reduced to 1 in 16 if the minimum criteria are extended to include a family member with 
VWF:RCo <40 IU dL-1 [38]. Once the minimal criteria for VWD diagnosis have been met, the next step 
would be to conduct laboratory analysis to characterize the type and severity of VWD, including a 
DDAVP test when appropriate, and determine the most suitable treatment. 
In summary, 90 years after the discovery of VWD, the diagnosis of type 1 VWD is still intriguing. Using 
a 2-step process for diagnosis, in which minimal criteria are used to select most-likely affected 
individuals (step 1) followed by full laboratory evaluation (step 2), may improve diagnosis of VWD. 
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However, this approach needs to be validated in large cohorts of patients (adults and children) with 
various types of VWD. 
Genetic diagnostics of VWD 
Clinical diagnosis of VWD and differentiation between its subtypes can be difficult, particularly when 
the phenotype is ambiguous. Genetic diagnostics may help facilitate correct differential diagnosis and 
ensure appropriate treatment and can also be useful in genetic counselling and prenatal diagnostics [39]. 
The VWF gene spans 178 kb of genomic DNA in 52 exons that encodes an 8.8 kb mRNA and a 2813-
amino acid protein [39, 40]. Over 160 normal variants of the VWF gene are known in the exons and 
closely flanking intronic sequences, and amino acid substitutions are reported at 30 residues [40]. Until 
recently, genetic analysis of the VWF gene has been limited to Sanger DNA sequencing, which, given 
the complexity of the VWF gene, has rendered genetic analysis and data interpretation complex and time 
intensive. However, the availability of next generation sequencing (NGS) now permits rapid 
simultaneous analysis of multiple genes. Additionally, large exon deletions and duplications can be 
detected by multiplex ligation-dependent probe amplification and micro-array analysis. The entire VWF 
gene coding sequence can now be readily analysed for phenotype/genotype correlation. 
Overall, pathogenic variants have been identified in >90% type 3 alleles, 50±90% type 2 alleles and 
<65% type 1 alleles. The location of key VWF mutations in type 1, 2 and 3 VWD are shown in Fig. 3 
[41, 42]. Type 1 VWD mutations can be found throughout the length of VWF, 75% being missense 
mutations and 25% other types of mutations [41]. A special form of type 1 VWD is "type 1C", which is 
characterized by a rapid clearance of VWF, for example caused by p.Arg1205His ("Vicenza mutation") 
[43, 44]. Type 3 VWD is the most severe form of VWD with mutations found throughout the entire 
coding region of the VWF gene. Over 80% are null mutations that result in complete lack of VWF 
production [41]. Type 2 VWD is subdivided into four subtypes, 2A, 2B, 2M and 2N. In most cases the 
multimer profile is normal, but loss or gain of specific cysteine residues in the D' and D3 assembly often 
lead to pleiotropic abnormalities where both reduced VWF levels and multimer abnormalities may be 
present. The key locations of VWF mutations in type 2 VWD are shown in Fig. 4 [41, 42]. Type 2A 
VWD is mostly caused by missense mutations predominantly in the A2 domain (exon 28) and the D3 
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domain (exons 25±27), which reduce binding to platelets. Type 2B VWD is limited to missense 
mutations in a discrete region of the A1 domain (exon 28), which enhance binding to platelets. Missense 
mutations in the A1 and A3 domains are found in type 2M VWD, leading to reduced binding of VWF 
to platelets or collagen. VWD type 2N missense mutations predominate in the D´ domain (exons 17±
20) and D3 domain (exons 24±25), leading to reduced binding of VWF to FVIII. If no mutations are 
found in this region, type 2N VWD can be excluded and the F8 gene should be screened for haemophilia 
A. 
Modern molecular genetic analysis has greatly enhanced our understanding of the molecular basis of 
VWD and its subtypes and continues to contribute considerably to improving differential diagnosis and 
management of patients with VWD. 
Phenotype/genotype correlation of patients with VWD 
The Centre de Référence de la Maladie de Willebrand (CRMW; French reference centre for VWD) was 
initiated in 2006 and is a collaboration of the main haemostasis departments in France (~50 university 
hospitals). The CRMW provides a unique national biologic platform for highly specialized analyses of 
phenotype, genotype and phenotype-genotype correlations in patients with VWD.  
To investigate the impact of phenotype-genotype on the VWD classification, data have been analysed 
for 1167 patients enrolled between 2007 and 2012 [45]. Patients previously diagnosed locally with VWD 
were included in the study. VWD phenotype was classified as type 1: VWF levels <30 IU dL-1 together 
with VWF:RCo (or VWF:CB)/VWF:Ag and FVIII:C/VWF:Ag ratios >0.6; type 2: decreased or normal 
VWF levels with a discrepancy between the antigenic and the functional levels (VWF:RCo (or 
VWF:CB)/VWF:Ag or FVIII:C/VWF:Ag ratios 0.6); or type 3: VWF levels <5 IU dL-1. Upon entry 
into the study, first-level phenotypic assays of VWF:Ag, VWF:RCo, FVIII:C, platelet count, activated 
partial thromboplastin time, ristocetin-induced platelet aggregation (RIPA) and platelet function 
analyzer-100 occlusion time were performed locally. Second-level VWF assays were performed by the 
CRMW biologic platform and included VWF multimeric distribution, VWF binding to platelet 
glycoprotein Ib, collagen and FVIII, and, in some patients, analysis of proteolytic fragments. Genomic 
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DNA was screened for sequence variations by direct sequencing of the VWF gene and, in some cases, 
by multiplex ligation-dependent probe amplification. Human Genome Variation Society (HGVS) 
nomenclature (www.hgvs.org/mutnomen/) was used for the sequence variations. The final classification 
of VWD was established by a working group taking into account the detailed phenotype, genotype, 
response to DDAVP (if available) and familial pedigree. The classification could be revised to reflect 
newly acquired information. 
Among the 1167 patients tested for both phenotype and genotype, there were 670 index cases (from 670 
unrelated families) and 497 affected family members. The gender ratio (F/M) of the 1167 patients was 
1.46 and age ranged from 6 months to 90 years (median 34 years). The percentage of O blood group 
was 56%, and in those patients, mean VWF:Ag levels were 19 IU dL-1 lower than in patients with non-
O blood group. The majority of patients were Caucasian (90%) and 10% were Afro-Caribbean. 
Of the 670 index cases, 167 (25%) were classified as type 1 VWD, 442 (66%) as type 2 VWD and 54 
(8%) as type 3 VWD (Fig. 5). The distribution of VWD subtypes was similar in the overall population. 
The percentage of patients with type 1 VWD (25%) was lower than previous estimates (~75%) [40]. 
This may be due to the stringent inclusion criteria (VWF < 30 IU dL-1) and the extensive identification 
of type 2 VWD in the CMRW cohort, which could otherwise have been classified as type 1 VWD. This 
is consistent with a European study in patients with type 1 VWD in which one-third of patients could 
have been reclassified as having type 2 VWD [35]. Data from the CRMW are generally consistent with 
those from a multicentre Spanish study [46]. The percentage of patients with types 1 and 3 VWD were 
similar in the CRMW and Spanish studies, although there was some variation in the distribution of type 
2 subtypes [45, 46]. 
Of the 167 index cases with type 1 VWD, 88 (53%) had type 1 mutations associated with a decreased 
synthesis/secretion of VWF, 33 (20%) exhibited mutations inducing an accelerated VWF clearance, 6 
(3.5%) had propeptide cleavage site mutations, and 34 (20%) exhibited heterozygous mutations and 
were considered as type 3 carriers; no mutation was found in 6 type 1 VWD patients (3.5%) [45]. In the 
54 type 3 VWD patients, 61 distinct sequence variations were identified that were novel mutations in 
two-thirds of cases. These sequence variations were spread over the VWF gene, with a predominance at 
10 
 
the N-terminal part of VWF (D domains), and consisted mainly of truncating mutations leading to silent 
alleles (82%) and a lower percentage of missense mutations (18%) [45]. The number of patients with 
type 3 VWD analysed from the CRMW database has now increased to 75 patients and 72 different 
mutations were identified throughout the VWF gene (25 (37%) located in the propeptide region and 47 
(65%) were novel mutations). Among the 75 patients, 27 (36%) were homozygous and 48 (64%) were 
compound heterozygous. For 9 patients (12%), only one VWF mutant allele was identified. In the 442 
patients with type 2 VWD, 118 distinct sequence variations were identified, including new mutations in 
one-third of cases [45]. These sequence variations were clustered in the A domains (types 2A, 2B, and 
2M) or D¶-D3 domains of VWF (type 2N) and were missense mutations in a large majority of cases 
(95%) [45]. A total of 102 patients (88 families) with type 2N have been diagnosed (2007 to 2014). In 
all cases, the VWF:FVIIIB assay was null or severely decreased, leading to low median FVIII:C levels 
of 19 (range 2±45) IU dL-1. 
The CRMW biologic platform has provided valuable data on the phenotype-genotype relationship in 
VWD. Studies are continuing to explore these relationships and further characterize VWD, particularly 
type 2 variants. The methodology is continually evolving to strengthen and broaden data capture. For 
example, bleeding score is now a mandatory inclusion criterion and NGS has been progressively 
introduced since 2013. The CRMW does not collect prospective data on clinical events as these are 
collected in the national registry FranceCoag Network, which is not currently connected to the CRMW 
database. Connection of these databases, if regulatory issues can be overcome, would be an important 
extension of the CRMW biologic platform.  
Diagnosis in the USA 
VWF testing is not standardized in the USA. For example, different centres use different VWF:RCo 
assays. In general, clinicians in the USA seem to be µRYHU-HGXFDWHG¶LQZKDWWKH9:)5&RVKRXOGEH
and less well educated on the importance of FVIII levels. Few centres can perform all of the increasingly 
complex subtyping tests and most samples are sent to the Blood Center of Wisconsin for analysis. The 
use of standardized tests for diagnosis of VWD is not the standard of care because diagnosis has serious 
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implications for life and health insurance. Premiums are higher for people with pre-existing conditions 
and hospitalization and treatment of a pre-existing condition are not covered.  
Treatment of VWD 
7RZDUGVSKDUPDFRNLQHWLFSRSXODWLRQPRGHOVIRU9:'$ORW³7R:L1´" 
Inter-individual variation in the pharmacokinetic (PK) parameters of replacement FVIII in patients with 
haemophilia A is well documented [47, 48]. This variation has stimulated interest in developing PK-
guided treatment regimens to optimize the treatment of patients with haemophilia A in the prophylactic 
setting [49, 50], although the use of this approach in the perioperative setting, beyond determination of 
pre-surgery FVIII in vivo recovery (IVR), has received less attention. PK-guided dosing of VWF/FVIII 
concentrates has been shown to be effective and safe in patients with VWD undergoing surgery [51, 52]. 
However, little is known about the PK parameters during surgery in patients with VWD and the 
correlation between pre- and post-surgery IVR is weak [53]. 
The ³patient tailored pharmacokinetic-guided dosing of clotting factor concentrates in bleeding 
disorders (OPTI-CLOT)´ study group is a multinational collaboration that aims to develop PK-guided 
perioperative treatment strategies for patients with bleeding disorders. The OPTI-CLOT studies are 
using perioperative data from clinical studies to construct a perioperative population PK model that can 
facilitate PK-guided iterative adaptive Bayesian dosing. During this procedure individual PK parameters 
are iteratively updated by combining PK information (e.g. dose, concentration, time) from the individual 
patient with a priori PK information from the population. To date, PK modelling has been applied to 
perioperative data from a Dutch retrospective study in patients with haemophilia A [54] and PK 
modelling of perioperative VWD data is currently underway. 
In the retrospective analysis of 119 haemophilia A patients undergoing 198 surgical procedures in the 
Netherlands, 45% of FVIII plasma concentrations were below the target range during the first 24 hours 
after surgery and 75% of the plasma concentration were above the target range after six days of 
hospitalization during perioperative management with FVIII concentrates [54] (Fig. 6). In addition, a 
reduction of 44% in the use of factor concentrates could have been achieved if plasma concentrations 
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had been maintained within target levels in the perioperative setting [54]. Population PK parameters 
were subsequently estimated in 75 adults undergoing 140 surgeries (median age: 48 years; median 
weight: 80 kg) and 44 children undergoing 58 surgeries (median age: 4.3 years; median weight: 18.5 
kg) [55] who participated in the Dutch study [54]. The model incorporated variations in PK parameters, 
for example, clearance decreased with increasing age (P < 0.01), increased in cases with blood group O 
(26%; P < 0.01), and there was a small decrease during major surgical procedures (7%; P < 0.01). The 
final PK model showed a good agreement between FVIII concentrations predicted by the model and 
those assessed by laboratory measurements [55]. An ongoing, randomized controlled trial is comparing 
iterative Bayesian PK-guided dosing with a standard dosing regimen in 60 patients with haemophilia A 
[56]. 
Iterative Bayesian PK modelling of perioperative data from patients with VWD treated with VWF/FVIII 
in the WiN study (ClinicalTrials.gov Identifier: NCT00510042) is currently being evaluated in the To 
WiN study. Data for 103 patients (148 procedures) are being evaluated. The majority of patients have 
type 1 (52%) or 2 (42%) VWD and 6% have type 3. The To WiN study will also include a similar 
evaluation of patients treated with DDAVP in the WiN study. In addition, a prospective study of iterative 
Bayesian PK-guided dosing in VWD and surgical and dental procedures (OPTI-CLOT: TARGET) is 
planned.  
Iterative Bayesian PK-guided dosing may allow individualization of perioperative therapy in patients 
with bleeding disorders and minimize under- or over-dosing during surgery. This approach has shown 
promise in patients with haemophilia A and data from patients with VWD will soon be available.  
Surgery in VWD 
Bleeding is a major surgical complication and is associated with mortality rates of 20% in cases of 
severe bleeding [57]. Approximately 75% to 90% of intraoperative and early postoperative bleeding can 
be attributed to technical factors [57]. However, acquired or congenital coagulopathies may favour, if 
not directly cause, surgical haemorrhage in some cases [57]. 
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Bleeding rates during surgery in patients with VWD have been shown to be high in the absence [58] 
and the presence [59] of perioperative haemostatic therapy. Bleeding rates during surgery, in the absence 
of perioperative haemostatic treatment, have been assessed in 311 patients (498 surgical procedures) 
who were diagnosed after surgery as definitive type 1 VWD (VWF:RCo 15±30 IU dL-1) and possible 
type 1 VWD (VWF:RCo 31±49 IU dL-1) [58]. Major haemorrhages occurred in 81 patients (26%) and 
87 surgical procedures (17.5%) and there was no statistically significant difference between the 
percentage of type 1 and possible type 1 VWD patients who had major haemorrhages (32.6% and 24.8%, 
respectively) [58]. In a multicentre, cross-VHFWLRQDO VWXG\ LQ SDWLHQWV ZLWK 9:)5&R  ,8 dL-1, 
bleeding complications were reported by 19 of 79 (24%) patients in 23 of 126 (18%) large joint 
procedures despite the use of perioperative haemostatic therapy in the majority of cases (81%) [59]. 
Possible causes of excessive bleeding in VWD patients during surgery include: anatomic changes due 
to prior bleeds, including neovascularization; insufficient haemostatic therapy; lack of stringent 
perioperative coagulation factor (VWF and FVIII) monitoring; lack of experience of 
surgeons/haematologists; and unnecessary use of anticoagulants in patients with bleeding disorder. 
The main treatment options for the perioperative management of VWD patients are DDAVP and 
replacement factor concentrates. European Haemophilia Treatment Standardisation Board (EHTSB) 
recommendations for the practical use of DDAVP [60] and factor concentrates [61] in VWD patients 
undergoing invasive procedures have recently been published. The suitability of DDAVP should be 
determined by a test infusion in candidate patients [60]. DDAVP is ineffective in type 3 VWD and its 
use in type 2B remains controversial due to the possibility of thrombocytopenia [60]. It can, however, 
be used effectively to cover minor surgery and dental procedures in most other VWD patients, although 
factor concentrate is generally preferred for major surgery [60]. Concomitant use of antifibrinolytics 
should be considered in most surgical interventions covered by DDAVP, particularly those involving 
the mucous membranes [60]. DDAVP is not recommended in patients with ischaemic heart disease; a 
history of stroke and/or peripheral vascular disease; myocardial infarction; heart failure; and 
hyponatremia [60]. Due to the risk of tachyphylaxis, DDAVP should not be given for more than 3±5 
days unless the patient can be monitored closely and switched to a concentrate if this occurs [60].  
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Factor concentrates (VWF/FVIII or VWF) are the treatment of choice in patients in whom DDAVP is 
ineffective or contraindicated [61]. EHTSB recommendations on the perioperative dosing and 
monitoring of factor concentrates in VWD patients undergoing surgery, together with other published 
guidelines/recommendations, are summarized in Table 1. In the most recent publication, the EHTSB 
highlighted a number of important issues [61]. For example, the ratio of VWF:RCo/FVIII:C in the 
concentrates varies significantly and doses of concentrate expressed in IU dL-1 are not interchangeable. 
Therefore, the recommended dose of a given concentrate should be specific to that concentrate as the 
required dose can be completely different when another concentrate is used. Similarly, because various 
types of VWD are characterized by great variability in VWF:RCo and FVIII:C, patients should have 
baseline values of VWF:RCo and FVIII:C measured before undergoing major surgery to plan treatment 
[61]. For monitoring, FVIII:C seems to be more important than VWF:RCo [61]. The parallel decay of 
VWF:RCo and FVIII:C curves with wilate® (Fig. 7), a VWF/FVIII with VWF:RCo/FVIII:C ratio of 1:1, 
may facilitate dosing and monitoring via either VWF:RCo or FVIII:C [62, 63], while differing half-lives 
for VWF:RCo and FVIII:C in other concentrates might require monitoring of both factor levels. 
Tranexamic acid was also recommended by the EHTSB as a valuable adjunctive agent that may be used 
concomitantly with concentrates in patients with VWD undergoing surgery, particularly those involving 
mucous membranes [61]. 
The perioperative management of patients with VWD can be challenging. Current treatment strategies 
are effective and will often include perioperative treatment with a factor concentrate. However, the 
dosing and monitoring of a given factor concentrate should be based on the properties of that concentrate 
and in accordance with its prescribing information, achieving critical target levels, but avoiding 
sustained excessive FVIII:C levels. 
Surgery in the USA 
PK analysis to guide dosing is not always done and is generally considered to be of academic interest. 
DDAVP is often used if the patient is responsive and combined with factor concentrate as required. 
When DDAVP is used it is important to monitor sodium levels to avoid water intoxication, particularly 
when fluid replacement during surgery is high. However, combination therapy is not the standard of 
15 
 
care in the US and most institutions only use factor concentrates. Achieving haemostasis during surgery 
is the most crucial IDFWRUDQGVKRXOGWDNHSUHFHGHQFHRYHUWKHFXUUHQWµRYHU-DQ[LHW\¶DERXW9:)DQG
FVIII levels during surgery and potential thrombosis. 
Treatment in the USA 
Available treatments in the USA are adjunctive therapies (DDAVP and antifibrinolytics) and factor 
replacement concentrates. Adjunctive therapies should not be overlooked. DDAVP is effective in many 
patients and may be particularly useful for the pre-operative reversal of aspirin effects or in patients with 
coexisting renal insufficiency. Antifibrinolytics may be particularly useful in the treatment of GI bleeds 
and in oral surgery. There are many different indications for concentrates. It is important to recognize 
that the US Food and Drug Administration (FDA) license a product for a specific indication, yet 
clinicians have the right to use any product any time for any reason. This raises the issue of potential 
litigation and, to protect themselves, institutions may not permit the use of products that are not 
specifically indicated. 
Angiogenesis in VWD 
VWF and angiodysplasia 
The prevention and treatment of gastrointestinal (GI) bleeding due to angiodysplasia is an important 
unresolved problem in the management of VWD patients. Angiodysplasia is characterized by 
degenerative lesions in the mucosal venules and capillaries in the GI tract associated with abnormal 
development of new blood vessels (angiogenesis) [64-68]. 
GI bleeding due to angiodysplasia is common in the elderly, with incidences ranging from 2.6% to 6.2% 
in the general population [69, 70]. Angiodysplasia-related GI bleeding is also a well-documented 
complication of VWD, although it occurs more frequently at a younger age and almost exclusively in 
patients lacking high molecular weight multimers (HMWMs) [65, 71, 72]. In a 2-year, prospective study 
of 107 patients, GI bleeding was much more frequent in patients with VWD characterized by a lack of 
HMWMs (type 2A) compared with type 2M VWD (Fig. 8).  
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Indirect evidence implicating a lack of HMWMs in angiodysplasia-related GI bleeding in VWD has 
come from studies in acquired von Willebrand syndrome, especially in patients with aortic stenosis or 
lymphoproliferative disorders [67, 68, 73, 74]. Aortic stenosis is often accompanied by a lack of 
HMWMs due to the increased shear stress exerted by the stenotic valve, which stretches the VWF 
molecule and increases susceptibility to proteolysis by ADAMTS-13 [75, 76]. Surgical correction of 
valve stenosis restores a normal multimeric pattern and abolishes bleeding complications [74]. The 
precise pathophysiological mechanisms underlying angiodysplasia-related GI bleeding in VWD have 
not yet been fully elucidated. However, in vitro data [77] have shown that low VWF in Weibel-Palade 
bodies of endothelial cells can promote angiogenesis and decrease vessel stability, which could lead to 
the vascular malformations typical of angiodysplasia [67]. 
The treatment of GI bleeding in patients with VWD and angiodysplasia is challenging due to frequent 
recurrence and the severity of bleeding, which usually increases with age [67, 68]. Replacement therapy 
with plasma-derived VWF/FVIII concentrates is the mainstay for the episodic treatment of acute GI 
bleeding in VWD, although the clinical effectiveness of VWF/FVIII concentrates in treating acute GI 
bleeds appears lower than for other bleeding sites [67, 68]. For example, a prospective study reported 
that a higher average daily dose (44 vs. 29 IU kg-1) and a longer duration of treatment (4.23 vs. 1.93 
days) were required for the treatment of GI bleeds compared with bleeds at other sites [78]. A similar 
picture has emerged in studies evaluating VWF/FVIII concentrates in secondary prophylaxis of 
recurrent GI bleeding, which have demonstrated the efficacy of VWF/FVIII concentrates but with lower 
efficacy than at other bleeding sites [67, 68]. In the largest published prophylaxis study, the VWD 
Prophylaxis Network retrospectively evaluated the efficacy of secondary prophylaxis with VWF/FVIII 
concentrates in 59 patients with clinically severe VWD that were unresponsive to other treatments [79]. 
Recurrent GI bleeding and epistaxis were the most common reasons to initiate prophylaxis, with each 
accounting for 23.6% (13/55) of cases [79]. Although the number of GI bleeds occurring during 
prophylaxis was significantly reduced, the percentage reduction in bleeding frequency (49%) was lower 
than that achieved for joint bleeding (86%) [67, 79].  
17 
 
A possible explanation for the lower efficacy of VWF/FVIII concentrates in treating GI may be related 
to the fact that replacement therapy does not replenish VWF within endothelial cells and platelets (only 
plasmatic VWF) and the HMWM composition of concentrates may be less efficient in treating GI bleeds 
compared with bleeds at other sites [68, 80].  
A number of alternative therapeutic approaches for the management of recurrent GI bleeds have been 
explored [67, 68]. These include oestrogen, progesterone, octreotide, tranexamic acid and DDAVP, 
although these treatments do not appear to be effective based on the limited evidence currently available. 
Drugs with anti-angiogenic properties have also been used, such as thalidomide and very large doses of 
atorvastatin (up to 80 mg daily). Although a few cases have reported positive effects on the frequency 
of GI bleeding, larger controlled studies are needed to establish the clinical usefulness of these therapies. 
Surgical approaches have not been shown to be consistently effective because the angiodysplastic 
lesions are usually multiple and diffuse in the GI tract. 
In summary, the prevention and treatment of GI bleeding due to angiodysplasia is an unresolved problem 
in the management of VWD patients. VWF/FVIII concentrates remain the mainstay therapy for the 
treatment of GI bleeds. Other strategies, such as rVWF and anti-angiogenic drugs, may have a future 
role in the prevention and treatment of GI bleeding due to angiodysplasia, but need further exploration. 
Reproductive tissue alterations in VWD 
Women with VWD are at increased risk of bleeds during the menstrual cycle and during pregnancy [81]. 
The most common symptom is menorrhagia (heavy menstrual bleeding), which is estimated to affect 
32±100% of women with VWD [23, 81]. Although VWF levels are known to rise in pregnancy, levels 
in women with VWD remain significantly lower than in their healthy counterparts [81]. Thus, women 
with VWD are at increased risk of bleeding complications associated with pregnancy and childbirth. 
A study conducted in pregnant women with type 1 or type 2 VWD investigated management of VWD 
during pregnancy. For inclusion in the study, patients had to have had at least two previous bleeding-
associated miscarriages or were experiencing bleeding during an ongoing pregnancy. Data are available 
for 61 patients (mean age of 32.7 (±11.3)) with type 1 VWD who received replacement therapy as 
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secondary prophylaxis or treatment during pregnancy. Live birth rate in treated patients was 80.3% (49 
of 61) compared with a live birth rate of 19.2% (28 of 146) prior to treatment (P < 0.0001). All 12 
pregnancy losses during replacement therapy occurred in the first trimester. Of the 118 historical 
pregnancy losses, 98 (83.1%) occurred in the first trimester, 9 (7.6%) occurred in the second trimester 
and 11 (9.3%) occurred in the third trimester.  
Complex and dynamic changes in vasculature occur during the menstrual cycle and during pregnancy 
and angiogenesis plays a vital role [81-83]. However, little is known about histological changes in 
women with VWD. In order to gain more insights into VWD during pregnancy, an animal study was 
initiated in 2016 and is due for completion in 2019. Several Meishan pigs [84] are being studied, 
suffering from type 3 VWD as well as type 1 VWD, and healthy controls. Collection of tissue from 
reproductive organs is planned for different stages of the menstrual cycle in non-pregnant animals of 
reproductive age, implantation, and placentation, respectively. Parameters being assessed include 
formation of blood vessels by haematoxylin and eosin staining, localization of angiogenesis mediators 
and receptors by immunohistochemistry, presence of causal mutations, and functional gene analysis 
using geneMANIA. Various angiogenic factors are being investigated in the study, including 
angiopoietin-1 (ANG-1), which promotes vascular maturation [83], vascular endothelial growth factor 
(VEGF), which is vital for vascular growth [83]DQGWKHĮ9ȕLQWHJULQZKLFKLVDFHOODGKHVLRQUHFHSWRU
[85]. 
Preliminary results from three reproductive organs ± uterus (endometrium), ovary, and oviduct- showed 
significantly fewer blood vessels with small lumens, whereas type 3 VWD animals have more thin 
walled vessels which appear dilated and filled with red blood cells (data not shown). Compared with 
control animals, there is decreased or even absent VWF staining in the uterine glands and endometrium 
RI9:'DQLPDOV:KLOHW\SHVDPSOHVVKRZVWURQJĮ9ȕVWDLQLQJWKLVLVLQFOHDUFRQWUDVWWRW\SH
samples. Ongoing studies include comparative quantification of the protein expression by real-time 
polymerase chain reaction (RT-PCR) to further elucidate the role of VWF in female reproduction and 
angiogenesis. 
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In conclusion, study results in VWD patients during pregnancy demonstrated a dramatic decrease in rate 
of pregnancy loss under VWD replacement therapy. Detailed analysis of the expression and localization 
of angiogenic factors in an animal model suggests that disrupted formation of vessels in several female 
organs may be an important pathogenic factor. 
VWF inhibitors  
Detecting inhibitors in VWD: an academic question? 
Anti-VWF inhibitors are a rare complication of replacement therapy that negates the haemostatic 
response to infused VWF concentrates [86]. Inhibitors develop in an estimated 5.8% to 9.5% of patients 
with type 3 VWD and have very rarely been reported in patients with other VWD types [86, 87]. In a 
retrospective analysis of the Italian Association of Hemophilia Centers (AICE), 96 of 1650 VWD 
patients had type 3 VWD (5.8%). Anti-VWF inhibitors were identified in 6 type 3 VWD patients, which 
corresponds to 6.2% (6/96) of type 3 patients and 0.4% (6/1650) of the total VWD population [88]. In 
contrast, FVIII inhibitors developed in 19.2% (316/1688) of patients with severe haemophilia A [88]. 
These anti-VWF inhibitors are allo-antibodies and might be related to deletions of the VWF gene, 
although it is important to recognize that not all gene deletions are associated with inhibitor development. 
In the late 1980s, gene defects associated with inhibitor development were identified using the Southern 
blot technique [89, 90]. In one study, homozygous complete VWF gene deletions were identified in the 
2 of the 19 type 3 VWD patients who developed inhibitors [89]. In another study, complete homozygous 
and heterozygous deletions were found in 6 of 10 type 3 VWD patients [90]. In the 1990s, one complete 
homozygous and one partial heterozygous deletion among 28 type 3 VWD German patients from 32 
families were identified [91], whereas one complete heterozygous VWF gene deletion was identified 
among 5 type 3 VWD Italian patients [92]. A common 253-kb deletion involving VWF and TMEM16B 
(ANO2) was subsequently identified in German and Italian patients with severe type 3 VWD [93]. In 
addition, partial homozygous VWF gene deletions including exons 1±3, 6±16, 42, 33±38, 22±43, 23±52 
and 17±18 have been described in 7 type 3 VWD patients; among these defects only the Alu-mediated 
deletion of exons 1±3 was found in several patients, constituting the most common defect in type 3 
VWD patients in Hungary [94]. 
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Whereas the Bethesda method with the Nijmegen modification is well established in the laboratory 
measurement of inhibitors in patients with haemophilia A, no general consensus has been reached for 
diagnosing anti-VWF inhibitors. Mix test assays, which are available in a small number of expert 
laboratories, mimic the Bethesda assays used in haemophilia A by measuring VWF/FVIII activities in 
patient-normal pool plasma after 2±4 hours incubation at 37qC. The titre of anti-VWF inhibitor is 
calculated by the actual dilution of VWD plasma inhibiting 50% of normal plasma pool diluted 1:2 
compared with control mixture (buffer instead of patient plasma). Several solid phase tests have been 
proposed, but these are not frequently used. The inhibitory activity of VWF inhibitors should be assessed 
by a range of measures, such as RIPA in normal platelet rich plasma, anti-VWF:Ag, anti-VWF:RCo, 
anti-VWF:CB and anti-FVIII. However, antibodies might also occur against µPXWH¶UHJLRQVRI9:)
molecules that cannot be identified with functional assays. An assay to test anti-VWF antibodies by 
using a sandwich ELISA (Ex-VWF-Plasma-HRP goat anti-human IgG-IgM) appears to be more 
sensitive than functional assays [95]. The outcome of an ongoing initiative of an ISTH subcommittee 
on VWF may lead to a more standardized approach to laboratory measurement of VWF inhibitors. 
In most reported cases, antibody development is heralded by poor clinical response to replacement 
therapy accompanied by lower than expected recovery of VWF with absence of the delayed and 
sustained raise of FVIII (secondary response to VWF). In cases where inhibitor titre is relatively low, it 
is not difficult to treat soft-tissue bleeds and to prevent bleeding in surgery. In patients with high-titre 
inhibitors, replacement therapy is not only ineffective, but it may also trigger life-threatening 
anaphylactic reactions associated with activation of the complement system [96]. A rise in antibody 
levels is usually seen 5±10 days after replacement therapy with VWF concentrates, with features typical 
of a secondary response to a foreign antigen. Recombinant FVIII (no VWF) was effective in a type 3 
patient with inhibitors undergoing emergency abdominal surgery [97]. Other possible therapeutic 
approaches are recombinant activated factor VII (rFVIIa) or a combination of rFVIII and rFVIIa [98-
100]. However, the use of rFVIII and rFVIIa in combination should take into account the possibility of 
thrombosis [100].  
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The 3WINTERS±IPS study ± Type 3 VWD International Registries and Inhibitor Prospective Study 
(3WINTERS±IPS, 2011±2018) has been set up to record clinical and laboratory data on a large cohort 
of at least 250 type 3 VWD patients at a network of European and Iranian centres [101]. The study 
comprises three phases (Fig. 9). In the first phase, ~250 type 3 patients were retrospectively identified. 
In the second phase, the diagnosis will be confirmed by centralized laboratory evaluation of the patients 
identified in the retrospective phase. Those patients with confirmed diagnosis of type 3 VWD 
expected) will then enter a 2-year, prospective third phase of the study. So far, a total of 266 patients 
(146 Europeans and 120 Iranians) have been identified with type 3 VWD in the retrospective phase and 
laboratory samples are undergoing confirmatory centralized testing.  
Even though the development of VWF inhibitors against replacement therapy is rare in patients with 
VWD, it is an important limitation of current therapy. 3WINTERS-IPS will provide important 
information on VWF inhibitors in type 3 patients and is expected to improve our understanding of the 
diagnosis and treatment of patients with type 3 VWD who develop inhibitors. 
Case report of immune tolerance induction in two brothers with VWF inhibitors 
Brother 1: Presented as a 7.5-year-old diagnosed with VWD at the age of 2.5 years after presenting with 
a foot contusion. At the age of 4 years he was hospitalized due to prolonged epistaxis and treated with 
VWF/FVIII concentrate every 12 hours. During this intensive treatment he developed mild shortness of 
breath responsive to albuterol, but subsequently did well with on-demand therapy. 
Brother 2: Presented as a 20-month-old diagnosed with VWD at birth (asymptomatic) due to the family 
history of VWD. He experienced frequent epistaxis and iron deficiency anaemia, which was treated on-
demand. He received about 15 prior VWF/FVIII concentrate infusions. Vague allergic symptoms were 
reported initially.  
Genetic testing confirmed that both brothers had a large homozygous deletion, VWF c.658_7887del, 
consistent with type 3 VWD. Prophylaxis was initiated for each with VWF/FVIII concentrate, but 
brothers manifested allergic symptoms, which worsened with subsequent doses. The older brother had 
mild shortness of breath; the younger experienced progressive symptoms of shortness of breath, urticaria, 
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tachycardia, and mild hypotension. Symptoms were responsive to IV diphenhydramine. Despite trialling 
a different VWF/FVIII concentrate, similar symptoms were observed, so further use of VWF/FVIII 
concentrate was avoided.  
While abroad, both were treated with a highly purified VWF concentrate. Although they did not develop 
allergic symptoms, bleed treatment was increasingly less effective. A mixing study confirmed the 
presence of neutralizing allo-antibodies.  
Skin pick and intradermal testing to VWF/FVIII concentrates and excipients were not suggestive of an 
IgE mediated allergic response. There is currently no standard approach to immune tolerance induction 
(ITI) in patients with VWD inhibitors. Following a graded challenge for the older brother and a 12-step 
desensitization protocol for the younger brother, ITI with 50 VWF:RCo IU kg-1 daily of a 1:1 
VWF/FVIII concentrate and mycophenolate mofetil 600 mg/m2 twice daily was initiated in both 
brothers.  
During approximately 8 months of treatment, the brothers received rFVIIa and aminocaproic acid to 
treat ongoing epistaxis, gingival bleeding and occasional injury. For procedures FVIII infusion and 
platelets were also used. Due to the ongoing symptoms and presence of VWF inhibitors, the ITI regimen 
was changed to rituximab 375 mg/m2 (4 doses) with continued VWF/FVIII concentrate treatment. 
Subsequent single rituximab doses were administered with B-cell recovery. This resulted in modest 
reduction of VWF inhibitor titres in both brothers and an improvement in clinical symptoms (Fig. 10).  
Memories of Margareta Blombäck on research on/about Åland and VWD 
I have had the great privilege of being involved in three research trips to the Åland Islands in 1957, 
1977 and 1992 [102].  
1957: Prior to the first trip in 1957, Inga Marie Nilsson and I had investigated many Swedish families 
ZLWKµSVHXGRKHPRSKLOLD¶DQGfound low FVIII and a prolonged bleeding time [103]. In addition, Birger 
Blombäck and I had purified a plasma fraction (Fraction I-0) that contained fibrinogen and FVIII, which 
stopped bleeding in patients with VWD, normalized FVIII and corrected the prolonged bleeding time 
[102]. On the 1957 trip to the Åland Islands, I was joined by colleagues from Stockholm (Professor Erik 
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Jorpes and Inga Marie Nilsson) in collaboration with Birger Blombäck and Stig-Arne Johansson. We 
wanted to investigate whether the µpseudohemophilia¶ in Åland and Sweden was the same. We analysed 
data from Family S described by Erik von Willebrand in 1926 and some other families. Investigations 
of 15 living patients showed that FVIII levels were 30±60% of normal, platelet activity was normal and 
there were no capillary defects. Infusion of Fraction I-0 to one patient resulted in normalization of FVIII 
activity and the prolonged bleeding time as we had previously seen in Swedish patients [104].  
1977: I returned to the Åland Islands together with Dag Nyman (then working in Stockholm). By this 
time, VWF:RCo and VWF:Ag assays were available. We found that the families could be divided into 
four categories [102, 105]: the survivors of family S, the original family, from Föglö, had the 
characteristics of type 1 VWD, i.e. they had similarly decreased levels of VWF:Ag and VWF:RCo in 
addition to normal or decreased levels of FVIII. One family had a ³SXUH´ SODWHOHW G\VIXQFWLRQ
(cyclooxygenase defect), one family had a mixture of type 1 VWD and a cyclooxygenase defect, and 
one family had an ³DVSLULQ´ type platelet dysfunction. 
1992: On my final research visit to the Åland Islands, I was joined by Dag Nyman (now again in Åland) 
and Zhiping Zhang from Stockholm. We collected DNA in VWD families and found exon 18 mutation 
in those with bleeding symptoms in Family S and 2 other families as well as in a 2-year-old boy with 
severe VWD (homozygote) and his parents (heterozygotes) [102, 106]. One cytosine deletion in exon 
18 was detected in all the families. Linkage analysis and genealogical studies suggest that the deletion 
in these families probably has a common origin also with the Swedish patients. 
Pier Mannucci concluded by paying tribute to the enormous contribution that Margareta had made to 
the scientific and clinical understanding of VWD. This sentiment was shared by all present, including 
Gerda S, the non-affected sister of the index case, Hjördis S. 
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Conclusions 
The Fifth Åland Island Meeting 2016 was a great success as were the previous meetings on these 
beautiful islands. The soul of the meeting is to convene a nice blend of international leaders in the 
field of VWD and younger, interested and motivated physicians. The scientific agenda is translational 
going from molecular genetics and molecules via laboratory issues and pharmacokinetics to 
epidemiology and clinical challenges, and of course, history. The meeting has a high scientific 
standard with plenty of room for discussions and networking. However, there is also another 
dimension that is unique: a visit to Hjördis´ house and graveyard gave a fundament for those who 
contribute to future research and development in the understanding and treatment of VWD. 
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TABLE AND FIGURE LEGENDS 
 
Table 1. Guidelines on the dosing and monitoring of VWD patients undergoing surgery. 
Figure 1. Visualizing the life cycle of WPBs at the ultrastructural level [10-12]. (A) The life cycle of 
WPBs. (B) Correlative light and electron microscopy of nascent WPB formation. (C) Serial block face 
scanning electron microscopy imaging of WPBs adjacent to (yellow), and connected to (red) the Golgi 
(green). The nucleus is shown in blue. (D) Electron tomography of WPB (green) with numerous 
connections to the Golgi (yellow). WPB, Weibel-Palade bodies. 
Figure 2. Clinical spectrum of VWD: implications for management. DDAVP, desamino D-arginine 
vasopressin; FVIII, coagulation factor VIII; IU, international units; VWD, von Willebrand disease; 
VWF, von Willebrand factor; VWF:RCo, von Willebrand factor ristocetin cofactor activity. 
Figure 3. Location of key VWF mutations in type 1, 2 and 3 VWD. VWD, von Willebrand disease; 
VWF, von Willebrand factor. 
Figure 4. Key locations of VWF mutations in type 2 VWD. VWD, von Willebrand disease; VWF, 
von Willebrand factor. 
Figure 5. Distribution of VWD types in 670 index cases [45]. VWD, von Willebrand disease. 
Figure 6. Achieved perioperative FVIII levels in a Dutch study in patients receiving clotting factor 
replacement therapy [54]. FVIII, coagulation factor VIII; IU, international units. 
Figure 7. wilate® is characterized by parallel VWF and FVIII decay curves [63]. FVIII:C, coagulation 
factor VIII activity; IU, international units; VWF:Ag, von Willebrand factor antigen content; 
VWF:RCo, von Willebrand factor ristocetin cofactor activity. 
Figure 8. Incidence rate/100 patient-years of spontaneous bleeding requiring treatment occurring in 
patients with type 2A or type 2M VWD [72]. VWD, von Willebrand disease. 
Figure 9. Overview of the 3WINTERS±IPS study. BAT, bleeding assessment tool; FVIII, coagulation 
factor VIII; VWD, von Willebrand disease; VWF, von Willebrand factor. 
Figure 10. Anti-VWF antibodies measured by ELISA during ITI. ELISA, enzyme-linked 
immunosorbent assay; FVIII, coagulation factor VIII; ITI, immune tolerance induction; MMF, 
mycophenolate mofetil; VWF, von Willebrand factor. 
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Table 1. Guidelines on the dosing and monitoring of VWD patients undergoing surgery. 
Guideline/ 
recommendation 
Dose, dosing frequency and monitoring 
Minor surgery Major surgery 
European 
Haemophilia 
Treatment 
Standardisation 
Board [61] 
Pre-operative dose should target 
FVIII:C 80±100 IU dL-1 and 
VWF:RCo 50 IU dL-1 
Postoperative doses should target 
trough levels of FVIII:C and 
VWF:RCo should be >50 and 30 
IU dL-1, respectively, on the day of 
surgery and for 3±5 days or until 
wound healing is complete. Simple 
dental extractions may require only 
one infusion immediately before 
the procedure, usually combined 
with tranexamic acid given orally 
for 7±10 days; the recommended 
peak target levels of both FVIII:C 
and VWF:RCo for this indication is 
>50 IU dL-1 
Pre-operative dose should target 
FVIII:C 80±100 IU dL-1 and 
VWF:RCo 50 IU dL-1 
Postoperative doses should target 
trough levels of FVIII:C of 80±100 
IU dL-1 on the day of surgery, 
decreasing to 50±80 IU dL-1 on days 
1±7 and 30±40 IU dL-1 by day 14 or 
until wound healing has been 
completed. For VWF:RCo, these 
levels are >50 IU dL-1 on the day of 
surgery, >30 IU dL-1 until day 14 or 
until wound healing is complete 
Evidence-based 
recommendations on 
the treatment of 
VWD in Italy [107] 
Daily or every other day doses of 
30±60 IU kg-1a of VWF/FVIII to 
maintain FVIII:C levels >30 U dL-1 
until healing is complete (usually 
2±4 days) 
Daily doses of 50 IU kg-1a of 
VWF/FVIII to maintain FVIII:C 
levels >50 U dL-1 until healing is 
complete (usually 5±10 days) 
Consensus Statement 
on the treatment of 
VWD in Spain [108]  
40±60 IU kg-1 every 24±48 hours to 
maintain FVIII:C >80±100 IU dL-1 
on the first 2 days and >50 IU dL-1 
on the following days 
40±60 IU kg-1 every 24±48 hours to 
maintain FVIII:C >30 IU dL-1, from  
5 to 7 days 
United Kingdom 
Haemophilia Centre 
Doctors Organization 
[109] 
FVIII:C should be monitored regularly in all major and most minor surgical 
procedures 
FVIII:C should be ,8P/-1 to cover major surgery and sustained above 
0.5 IU mL-1 in the postoperative period 
The VWF:RCo should be monitored in major surgical procedures, 
particularly in the perioperative period. The VWF:RCo should be 
maintained above 0.5 IU mL-1 in the perioperative period 
USA National Heart, 
Lung, and Blood 
Institute [23] 
30±60 U kg-1 (loading doseb) and 
20±40 U kg-1 (maintenance dose) 
every 12±48 hours 
Trough VWF:RCo and FVIII >50 
IU/dL for 3±5 days 
40±60 U kg-1 (loading doseb) and 20±
40 U kg-1 (maintenance dose) every 
8±24 hours 
Trough VWF:RCo and FVIII >50 
IU/dL for 7±14 days 
aDosage indicated for VWD patients with FVIII:C/VWF:RCo levels <10 U dL-1. 
bLoading dose is in VWF:RCo IU dL-1. 
FVIII:C, factor VIII coagulant activity; IU, international units; VWF:RCo, von Willebrand factor ristocetin 
cofactor activity; U, units. 
 
